Open-label trial: Effect of weekly risedronate immediately after transplantation in kidney recipients

Transplantation

Volumn 89, Issue 12, 2010, Pages 1476-1481

  Torregrosa, José Vicente ^a   Fuster, David ^a   Gentil, Miguel Ángel ^b   Marcen, Roberto ^c   Guirado, Luís ^d   Zarraga, Sofía ^e   Bravo, Juan ^f   Burgos, Dolores ^g   Monegal, Ana ^a   Muxí, Africa ^a   García, Sagrario ^h  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d FUNDACIÓ PUIGVERT   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Bone fractures; Bone mineral density; Kidney recipients; Risedronate; Vascular calcifications

Indexed keywords

BASILIXIMAB; CALCIUM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCLONAL ANTIBODY; PREDNISONE; RISEDRONIC ACID; TACROLIMUS; VITAMIN D;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; GRAFT RECIPIENT; HIP FRACTURE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; ADULT; BONE DENSITY; CALCIUM; ETIDRONIC ACID; FEMALE; FEMUR NECK; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D;

EID: 77954083368     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181dc13d0     Document Type: Article

References (16)

1. Katz IA, Epstein S. Perspectives. Post-transplantation bone disease. J Bone Miner Res 1992; 7: 123.
2. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med 1998; 104: 459.
3. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplant. J Bone Miner Res 1999; 14: 456.
4. Mitterbauer C, Oberbauer R. Bone disease after kidney transplantation. Transpl Int 2008; 21: 615.
5. Nisbeth U, Lindh E, Ljunghall S, et al. Increased fracture rateindiabetes mellitus and females after renal transplantation. Transplantation 1999; 67: 1218.
6. Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669.
7. Fan SL, Almond MK, Ball E,et al. Pamidronate therapyasprevention of bone loss following renal transplantation. Kidney Int 2000; 57: 684.
8. Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003; 63: 1130.
9. Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation.J Am Soc Nephrol2001; 12: 1530.
10. Kovac D, Lindic J, Kandus A, et al. Prevention of bone loss with alen-dronate in kidney transplant recipients. Transplantation 2000; 70: 1542.
11. Torregrosa JV, Moreno A, Gutierrez A, et al. Alendronate for treatment of renal transplant patients with osteoporosis. Transplant Proc2003; 35: 1393.
12. Torregrosa JV, Fuster D, Pedroso S, et al. Weekly risedronate in kidney transplant patients with osteopenia. Transpl Int 2007; 20: 708.
13. Torregrosa JV, Cannata Andia J, Bover J, et al. SEN Guidelines. Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients. Nefrologia 2008; 28(suppl 1): 1.
14. Nowacka-Cieciura E, CieciuraT,BaczkowskaT, et al. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation. Transplant Proc 2006; 38: 165.
15. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254.
16. Cruz DN, Brickel HM, Wysolmerski JJ. Treatment of osteoporosis and osteopeniainlog-term renal transplant patients with alendronate. Am J Transplant 2002; 2: 62.